A Sanofi-Aventis drug currently in phase III has been predicted as a future blockbuster in breast cancer treatment. Sanofi’s BSI-201 …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

